Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II open label study that looks at the efficacy and toxicity of Ofatumumab
monotherapy in patients with relapsed and/or refractory diffuse large B-cell lymphoma
(DLBCL). Patients will receive weekly infusions of Ofatumumab of 1000 mg each for 8 weeks
(induction phase) followed by continuing the study drugs every other week in subsequent
cycles (maintenance phase). Each 4 weeks of therapy will be calculated as one cycle.
Treatment will continue until disease progression, toxicity, patient's withdrawal, or
investigator's discretion.